Atossa Therapeutics (ATOS) EBITDA Margin (2011 - 2015)
Atossa Therapeutics (ATOS) posted quarterly EBITDA Margin of 140733.62% for Q4 2015, down 1805337.0% year-over-year from N/an in Q4 2014, and down 14.72% quarter-over-quarter from 122680.24% in Q4 2014.
Atossa Therapeutics (ATOS) EBITDA Margin (2011 - 2015) Analysis & Trends
Atossa Therapeutics (ATOS) has reported EBITDA Margin for 5 consecutive years, with 140733.62% the latest figure, recorded in Q4 2015.
- In Q4 2015, EBITDA Margin fell 1805337.0% year-over-year to 140733.62%; the TTM figure through Sep 2016 stood at 459752.84% (up 4206039.0% YoY), while the FY2015 annual figure was 725746.19%, down 69542323.0% from the prior year.
- EBITDA Margin retreated to 140733.62% in Q4 2015 per ATOS's latest filing, from 122680.24% in the prior quarter.
- Across five years, EBITDA Margin topped out at 762.07% in Q4 2013 and bottomed at 140733.62% in Q4 2015.
- Historically, EBITDA Margin has averaged 42437.16% across 5 years, with a median of 23356.94% in 2014.
- Annual changes were most pronounced in 2012 — EBITDA Margin soared 7808681 bps — and 2014, when it sank 12344231 bps.
- Atossa Therapeutics' EBITDA Margin stood at 79818.93% in 2011, then soared by 98 bps to 1732.12% in 2012, then surged by 144 bps to 762.07% in 2013, then tumbled by 16198 bps to 122680.24% in 2014, then decreased by 15 bps to 140733.62% in 2015.
- Business Quant data shows ATOS's EBITDA Margin at 140733.62% in Q4 2015, 122680.24% in Q4 2014, and 94724.31% in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 19.75% |
| 10 | Atossa Therapeutics | 22.72 Mn | 22.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -140,733.62% |
| Dec 31, 2014 | -122,680.24% |
| Sep 30, 2014 | -94,724.31% |
| Jun 30, 2014 | -32,268.69% |
| Mar 31, 2014 | -9,993.89% |
| Dec 31, 2013 | 762.07% |
| Sep 30, 2013 | -4,851.15% |
| Jun 30, 2013 | -2,144.07% |
| Mar 31, 2013 | -14,445.19% |
| Dec 31, 2012 | -1,732.12% |
| Sep 30, 2012 | -1,075.69% |
| Jun 30, 2012 | -37,305.98% |
| Mar 31, 2012 | -53,108.40% |
| Dec 31, 2011 | -79,818.93% |